Prognostic significance of occult lymph node metastases in node-negative breast cancer

被引:132
作者
Clare, SE
Sener, SF
Wilkens, W
Goldschmidt, R
Merkel, D
Winchester, DJ
机构
[1] NORTHWESTERN UNIV, EVANSTON HOSP, DEPT SURG, EVANSTON, IL 60201 USA
[2] NORTHWESTERN UNIV, EVANSTON HOSP, DEPT PATHOL, EVANSTON, IL 60201 USA
[3] NORTHWESTERN UNIV, EVANSTON HOSP, DEPT MED, EVANSTON, IL 60201 USA
[4] NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA
关键词
occult metastases; breast cancer; cytokeratin (antikeratin) antibodies;
D O I
10.1007/BF02303667
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lymph node status, established by a single hematoxylin and eosin (H&E) section from each node, remains an important prognostic indicator in patients with breast cancer, but used alone it is insufficient to identify patients who will develop metastatic disease. This study was conducted to assess the significance of detecting occult metastases in 86 patients with breast cancer originally reported to be histologically node negative. None of the patients received adjuvant systemic therapy. Methods: Five additional levels from formalin-fixed, paraffin-embedded nodes were examined at 150-mu m intervals with H&E staining and a cocktail of antikeratin antibodies (AE1/AE3) recognizing low molecular weight acidic keratins. Results: Nodes from 11 (12.8%) of 86 patients contained occult metastases. All metastases identified by cytokeratin antibody were also detected in H&E-stained sections. With median followup of 80 months, distant metastases occurred in five of 11 occult node-positive patients (45%) and 13 of 75 patients whose nodes were negative on review (17%). Median time to recurrence was 89 months for occult node-positive patients and not yet reached for node-negative patients (p = 0.048). The disease-specific 5-year survival rate was 90% for occult node-positive patients and 95% for node-negative patients. Conclusions: The presence of occult metastases shortened the disease-free interval and suggested that more diligent axillary staging would more accurately identify patients who would benefit from systemic adjuvant treatment.
引用
收藏
页码:447 / 451
页数:5
相关论文
共 28 条
[1]   MAMMOGRAPHIC SCREENING AND MORTALITY FROM BREAST-CANCER - THE MALMO MAMMOGRAPHIC SCREENING TRIAL [J].
ANDERSSON, I ;
ASPERGREN, K ;
JANZON, L ;
LANDBERG, T ;
LINDHOLM, K ;
LINELL, F ;
LJUNGBERG, O ;
RANSTAM, J ;
SIGFUSSON, B .
BRITISH MEDICAL JOURNAL, 1988, 297 (6654) :943-948
[2]   THE IMMUNOHISTOCHEMICAL DETECTION OF LYMPH-NODE METASTASES FROM INFILTRATING LOBULAR CARCINOMA OF THE BREAST [J].
BUSSOLATI, G ;
GUGLIOTTA, P ;
MORRA, I ;
PIETRIBIASI, F ;
BERARDENGO, E .
BRITISH JOURNAL OF CANCER, 1986, 54 (04) :631-636
[3]  
FISHER B, 1975, SURG GYNECOL OBSTET, V140, P528
[4]  
FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO
[5]  
2-3
[6]  
FISHER B, 1970, SURG GYNECOL OBSTETR, V131, P79
[7]  
FISHER ER, 1978, CANCER, V42, P2025, DOI 10.1002/1097-0142(197810)42:4<2025::AID-CNCR2820420452>3.0.CO
[8]  
2-J
[9]   IMPROVED AXILLARY STAGING OF BREAST-CANCER WITH SENTINEL LYMPHADENECTOMY [J].
GIULIANO, AE ;
DALE, PS ;
TURNER, RR ;
MORTON, DL ;
EVANS, SW ;
KRASNE, DL .
ANNALS OF SURGERY, 1995, 222 (03) :394-401
[10]  
GOLDHIRSCH A, 1990, LANCET, V335, P1565